Article Figures & Tables
Figures
- Figure 1:
Study flow chart.
- Figure 2:
Age-standardized incidence per 100 000 person-years of first primary cancers among people with HIV, by calendar period and cancer category. Note: ADC = AIDS-defining cancer, CI = confidence interval, NADC = non-AIDS-defining cancer.
- Figure 3:
Age-standardized incidence per 100 000 person-years of first primary cancers among people with HIV, by calendar period and sex. Note: CI = confidence interval.
Tables
- Table 1:
Distribution of baseline characteristics of adults living with HIV in Ontario, Canada, 1997–2020
Characteristic No. (%) of participants* Standardized difference† Female
n = 4109Male
n = 15 294Total
n = 19 403Age yr, median (IQR) 35 (29–44) 37 (30–44) 36 (30–44) 0.06 Age category, yr 18–29 1099 (26.7) 3663 (24.0) 4762 (24.5) 0.06 30–39 1496 (36.4) 5659 (37.0) 7155 (36.9) 0.01 40–49 857 (20.9) 3857 (25.2) 4714 (24.3) 0.10 50–59 382 (9.3) 1540 (10.1) 1922 (9.9) 0.03 60–69 157 (3.8) 419 (2.7) 576 (3.0) 0.06 70–79 67 (1.6) 119 (0.8) 186 (1.0) 0.08 ≥ 80 51 (1.2) 37 (0.2) 88 (0.5) 0.12 Period of cohort entry 1997–1999 579 (14.1) 2787 (18.2) 3366 (17.3) 0.11 2000–2003 642 (15.6) 2296 (15.0) 2938 (15.1) 0.02 2004–2007 778 (18.9) 2425 (15.9) 3203 (16.5) 0.08 2008–2011 728 (17.7) 2444 (16.0) 3172 (16.3) 0.05 2012–2015 640 (15.6) 2603 (17.0) 3243 (16.7) 0.04 2016–2020 742 (18.1) 2739 (17.9) 3481 (17.9) 0.01 Neighbourhood income quintile Missing 24 (0.6) 94 (0.6) 118 (0.6) 0 1 (lowest) 1845 (44.9) 4661 (30.5) 6506 (33.5) 0.30 2 893 (21.7) 3389 (22.2) 4282 (22.1) 0.01 3 573 (13.9) 2600 (17.0) 3173 (16.4) 0.08 4 418 (10.2) 2254 (14.7) 2672 (13.8) 0.14 5 (highest) 356 (8.7) 2296 (15.0) 2652 (13.7) 0.20 Rurality Missing 13 (0.3) 30 (0.2) 43 (0.2) 0.02 Urban 3949 (96.1) 14703 (96.1) 18652 (96.1) 0 Rural 147 (3.6) 561 (3.7) 708 (3.6) 0 Region of birth Born in Canada 2513 (61.2) 11972 (78.3) 14485 (74.7) 0.38 Immigrant born in a country with low HIV prevalence 499 (12.1) 2174 (14.2) 2673 (13.8) 0.06 Immigrant born in a country with high HIV prevalence‡ 1097 (26.7) 1148 (7.5) 2245 (11.6) 0.53 Immigration status Long-term resident (Born in Canada or immigrated before 1986) 2513 (61.2) 11972 (78.3) 14485 (74.7) 0.38 Long-term immigrant (≥ 10 yr in Canada) 254 (6.2) 1025 (6.7) 1279 (6.6) 0.02 Recent immigrant to Canada (0–10 yr in Canada) 776 (18.9) 1664 (10.9) 2440 (12.6) 0.23 Immigrated after HIV diagnosis 566 (13.8) 633 (4.1) 1199 (6.2) 0.34 Comorbidity burden (number of CADGs)§ Low (1–4 CADGs) 1560 (38.0) 6135 (40.1) 7695 (39.7) 0.04 Moderate (5–9 CADGs) 1422 (34.6) 6619 (43.3) 8041 (41.4) 0.18 High (10–12 CADGs) 1127 (27.4) 2540 (16.6) 3667 (18.9) 0.26 RUB¶ Low expected resource use (0–2 RUBs) 1–5 (< 0.1) 15–19 (< 0.1) 20 0.01 Moderate expected resource use (3 RUBs) 2089 (50.8) 8876 (58.0) 10965 (56.5) 0.14 High expected resource use (4–5 RUBs) 2015–2019 (49.1) 6399–6403 (41.9) 8418 (43.4) 0.15 Note: CADG = collapsed Aggregated Diagnosis Groups, IQR = interquartile range, RUB = Resource Utilization Band.
↵* Unless indicated otherwise. Ranges are shown to suppress small cell sizes.
↵† More than 0.1 was considered a meaningful standardized difference.
↵‡ Regions of Africa and the Caribbean were considered regions with high HIV prevalence.
↵§ Comorbidity burden, based on type of illness in the 2 years preceding cohort entry, was assessed using the Johns Hopkins Adjusted Clinical Group System CADGs, with fewer than 5 CADGs indicating low burden, 5–9 CADGs indicating medium burden and 10–12 CADGs indicating high burden.
↵¶ Expected health care use was assessed using the Johns Hopkins Adjusted Clinical Group RUBs, based on 6 categories, with 0 being no health care use and 5 being the highest expected use.
- Table 2:
Incident primary cancers diagnosed among people with HIV in Ontario, Canada, 1997–2020
Variable No. (%) of incident cancers* Females
n = 239Males
n = 1036Total cohort
n = 1275Infection-unrelated cancers 153 (64.0) 478 (46.1) 631 (49.5) All infection-related cancers 86 (36.0) 558 (53.9) 644 (50.5) ADCs 57 (23.8) 329 (31.8) 386 (30.3) Infection-related NADCs 29 (12.1) 229 (22.1) 258 (20.2) All NADCs (infection-unrelated and infection-related NADCs) 182 (76.1) 707 (68.2) 889 (69.7) Note: ADC = AIDS-defining cancer, NADC = non-AIDS defining cancer.
↵* Column percentages do not sum to 100% as cancers can be in more than 1 category.
- Table 3:
Two-, 5- and 10-year person-based prevalence of cancer as of end of follow-up (Nov. 1, 2020)
Variable No. of people diagnosed with cancer Prevalence, % (95% CI) 2-year prevalence (cancers diagnosed since 2018) All cancers 139 0.8 (0.7–0.9) Infection-unrelated cancer 91 0.5 (0.4–0.6) Infection-related cancer 48 0.3 (0.2–0.4) Infection-related NADC 26 0.2 (0.1–0.2) ADC 22 0.1 (0.1–0.2) 5-year prevalence (cancers diagnosed since 2015) All cancers 313 1.8 (1.6–2.0) Infection-unrelated cancer 197 1.2 (1.0–1.3) Infection-related cancer 116 0.7 (0.5–0.8) Infection-related NADC 60 0.3 (0.3–0.4) ADC 56 0.3 (0.2–0.4) 10-year prevalence (cancers diagnosed since 2010) All cancers 510 3.0 (2.7–3.2) Infection-unrelated cancer 289 1.7 (1.5–1.9) Infection-related cancer 221 1.3 (1.1–1.5) Infection-related NADC 103 0.6 (0.5–0.7) ADC 118 0.7 (0.6–0.8) Note: ADC = AIDS-defining cancer, CI = confidence interval, NADC = non-AIDS defining cancer.
In this issue
Article tools
Related Articles
Cited By...
- No citing articles found.